Patents by Inventor Konrad Rejdak

Konrad Rejdak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF CLADRIBINE FOR TREATING IMMUNE BRAIN DISEASE
    Publication number: 20240041911
    Abstract: 2-Chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of autoimmune encephalitis, hereinafter referred to as AE, in a patient diagnosed with AE.
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Inventor: KONRAD REJDAK
  • USE OF CLADRIBINE FOR TREATING AUTOIMMUNE NEUROMUSCULAR DISEASE
    Publication number: 20200163986
    Abstract: The present invention relates to the use of 2-chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof, for treating or ameliorating an autoimmune, neuromuscular disorder, e.g. the autoimmune neuromuscular disorder myasthenia gravis (MG).
    Type: Application
    Filed: June 28, 2018
    Publication date: May 28, 2020
    Inventor: Konrad Rejdak
  • Use of cladribine for treating autoimmune inflammatory disease
    Patent number: 10350231
    Abstract: 2-Chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: July 16, 2019
    Assignee: Chord Therapeutics S.a.r.l.
    Inventors: Arthur Henry Roach, Konrad Rejdak
  • USE OF CLADRIBINE FOR TREATING AUTOIMMUNE INFLAMMATORY DISEASE
    Publication number: 20160339049
    Abstract: 2-Chloro-2?-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.
    Type: Application
    Filed: January 27, 2015
    Publication date: November 24, 2016
    Inventors: Arthur Henry Roach, Konrad Rejdak